Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial (2025)
- Authors:
- Autor USP: MUSSI, MARISA MARCIA - FMRP
- Unidade: FMRP
- DOI: 10.1080/21645515.2025.2450120
- Subjects: VACINAS; ADOLESCENTES; IMUNOGENICIDADE DA VACINA
- Keywords: Ad26.COV2.S; COVID-19 vaccine; Adolescent; Dose-range study; Immunogenicity; Safety; Shelf life; Virus vector vaccine
- Language: Inglês
- Imprenta:
- Source:
- Título: Human Vaccines & Immunotherapeutics
- ISSN: 2164-5515
- Volume/Número/Paginação/Ano: v. 21, n. 1, art. 2450120, p. 1-12, 2025
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc
-
ABNT
TICA, Jelena et al. Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial. Human Vaccines & Immunotherapeutics, v. 21, n. 1, p. 1-12, 2025Tradução . . Disponível em: https://doi.org/10.1080/21645515.2025.2450120. Acesso em: 09 jan. 2026. -
APA
Tica, J., Rezelj, V. V., Baron, B., Zaidman, J., Fairlie, L., Scheper, G., et al. (2025). Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial. Human Vaccines & Immunotherapeutics, 21( 1), 1-12. doi:10.1080/21645515.2025.2450120 -
NLM
Tica J, Rezelj VV, Baron B, Zaidman J, Fairlie L, Scheper G, Struyf F, Douoguih M, Le Gars M, Mussi MM. Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial [Internet]. Human Vaccines & Immunotherapeutics. 2025 ; 21( 1): 1-12.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1080/21645515.2025.2450120 -
Vancouver
Tica J, Rezelj VV, Baron B, Zaidman J, Fairlie L, Scheper G, Struyf F, Douoguih M, Le Gars M, Mussi MM. Safety and immunogenicity of Ad26.COV2.S in adolescents: phase 2 randomized clinical trial [Internet]. Human Vaccines & Immunotherapeutics. 2025 ; 21( 1): 1-12.[citado 2026 jan. 09 ] Available from: https://doi.org/10.1080/21645515.2025.2450120 - Chlamydia trachomatis and Neisseria gonorrhoeae in HIV-infected pregnant women and adverse infant outcomes
- Syphilis in HIV-infected mothers and infants
- First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial
- Particularidades imunológicas do pré-termo extremo: um desafio para a prevenção da sepse hospitalar
- Etravirine in treatment-experienced, HIV-1-infected chidren and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study
- Lower respiratory tract infections and hospitalizations among HIV-exposed, uninfected infants born in Latin America
- Detecção qualitativa e quantitativa de partículas virais e anticorpos contra o vírus da Hepatite B (VHB) no sangue e leite de nutrizes AGHBS/Anti-HBc e anti-HBs/anti-HBc positivas
- Prevalência dos marcadores da infecção pelo vírus da hepatite B (VHB) em parturientes: destaque para detecção isolada do marcador anti-HBc
- Three postpartum antiretroviral regimens to prevent intrapartum HIV infection
- Birth prevalaence and characteristics of congenital toxoplasmosis in Sergipe, North-east Brazil
Informações sobre o DOI: 10.1080/21645515.2025.2450120 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003250198.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
